Site-directed RNA repair of endogenous Mecp2 RNA in neurons

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 44, 2017, Pages E9395-E9402

  Sinnamon, John R ^a   Kim, Susan Y ^a   Corson, Glen M ^a   Song, Zhen ^a   Nakai, Hiroyuki ^a   Adelman, John P ^a   Mandel, Gail ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

ADAR2; MeCP2; Rett syndrome; RNA editing

Indexed keywords

ADENOSINE; ADENOSINE DEAMINASE; ADENOSINE DEAMINASE ACTING ON RNA; DEAMINASE; DOUBLE STRANDED RNA; GUANOSINE; GUIDE RNA; INOSINE; MESSENGER RNA; METHYL CPG BINDING PROTEIN 2; RNA; SMALL NUCLEAR RNA; SYNAPSIN I; UNCLASSIFIED DRUG; VIRUS LARGE T ANTIGEN; RNA BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA BINDING; ENTEROBACTERIA PHAGE LAMBDA; ENZYME ACTIVE SITE; GENE MUTATION; HUMAN; MOUSE; NERVE CELL; NERVE CELL CULTURE; NEUROBLASTOMA CELL; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN TARGETING; RETT SYNDROME; RNA BINDING; RNA EDITING; RNA REPAIR; SITE DIRECTED MUTAGENESIS; ANIMAL; CELL CULTURE; DISEASE MODEL; DNA METHYLATION; GENETICS; MUTATION; PHYSIOLOGY;

ADENOSINE DEAMINASE; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA METHYLATION; HUMANS; METHYL-CPG-BINDING PROTEIN 2; MICE; MUTATION; NEURONS; RETT SYNDROME; RNA; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 85032748097     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1715320114     Document Type: Article

References (77)

1. Amir RE, et al. (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23:185–188.
2. Neul JL, et al.; RettSearch Consortium (2010) Rett syndrome: Revised diagnostic criteria and nomenclature. Ann Neurol 68:944–950.
3. Percy AK, et al. (2010) Rett syndrome diagnostic criteria: Lessons from the natural history study. Ann Neurol 68:951–955.
4. Schüle B, Armstrong DD, Vogel H, Oviedo A, Francke U (2008) Severe congenital encephalopathy caused by MECP2 null mutations in males: Central hypoxia and reduced neuronal dendritic structure. Clin Genet 74:116–126.
5. Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 27:322–326.
6. Lioy DT, et al. (2011) A role for glia in the progression of Rett’s syndrome. Nature 475: 497–500.
7. Chen RZ, Akbarian S, Tudor M, Jaenisch R (2001) Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 27: 327–331.
8. Luikenhuis S, Giacometti E, Beard CF, Jaenisch R (2004) Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc Natl Acad Sci USA 101: 6033–6038.
9. Ross PD, et al. (2016) Exclusive expression of MeCP2 in the nervous system distinguishes between brain and peripheral Rett syndrome-like phenotypes. Hum Mol Genet 25:4389–4404.
10. Belichenko NP, Belichenko PV, Mobley WC (2009) Evidence for both neuronal cell autonomous and nonautonomous effects of methyl-CpG-binding protein 2 in the cerebral cortex of female mice with Mecp2 mutation. Neurobiol Dis 34:71–77.
11. Belichenko PV, et al. (2009) Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: Evidence for disruption of neuronal networks. J Comp Neurol 514:240–258.
12. Fukuda T, Itoh M, Ichikawa T, Washiyama K, Goto Y (2005) Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. J Neuropathol Exp Neurol 64:537–544.
13. Kishi N, Macklis JD (2004) MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol Cell Neurosci 27:306–321.
14. Robinson L, et al. (2012) Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome. Brain 135:2699–2710.
15. Tropea D, et al. (2009) Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA 106:2029–2034.
16. Stuss DP, Boyd JD, Levin DB, Delaney KR (2012) MeCP2 mutation results in compartment-specific reductions in dendritic branching and spine density in layer 5 motor cortical neurons of YFP-H mice. PLoS One 7:e31896.
17. Armstrong D, Dunn JK, Antalffy B, Trivedi R (1995) Selective dendritic alterations in the cortex of Rett syndrome. J Neuropathol Exp Neurol 54:195–201.
18. Li Y, et al. (2013) Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 13:446–458.
19. Belichenko PV, Oldfors A, Hagberg B, Dahlström A (1994) Rett syndrome: 3-D confocal microscopy of cortical pyramidal dendrites and afferents. Neuroreport 5:1509–1513.
20. Bauman ML, Kemper TL, Arin DM (1995) Pervasive neuroanatomic abnormalities of the brain in three cases of Rett’s syndrome. Neurology 45:1581–1586.
21. Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007) Reversal of neurological defects in a mouse model of Rett syndrome. Science 315:1143–1147.
22. Sinnett SE, et al. (2017) Improved MECP2 gene therapy extends the survival of MeCP2-null mice without apparent toxicity after intracisternal delivery. Mol Ther Methods Clin Dev 5:106–115.
23. Gadalla KKE, et al. (2017) Development of a novel AAV gene therapy cassette with improved safety features and efficacy in a mouse model of Rett syndrome. Mol Ther Methods Clin Dev 5:180–190.
24. Garg SK, et al. (2013) Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. J Neurosci 33:13612–13620.
25. Gadalla KK, et al. (2013) Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol Ther 21:18–30.
26. Van Esch H, et al. (2005) Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet 77:442–453.
27. Skene PJ, et al. (2010) Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol Cell 37:457–468.
28. Ballas N, Lioy DT, Grunseich C, Mandel G (2009) Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat Neurosci 12:311–317.
29. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY (2002) Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet 11:115–124.
30. Sugino K, et al. (2014) Cell-type-specific repression by methyl-CpG-binding protein 2 is biased toward long genes. J Neurosci 34:12877–12883.
31. Linhoff MW, Garg SK, Mandel G (2015) A high-resolution imaging approach to investigate chromatin architecture in complex tissues. Cell 163:246–255.
32. Fyfe S, Cream A, de Klerk N, Christodoulou J, Leonard H (2003) InterRett and RettBASE: International Rett syndrome association databases for Rett syndrome. J Child Neurol 18:709–713.
33. Bass BL, Weintraub H (1988) An unwinding activity that covalently modifies its double-stranded RNA substrate. Cell 55:1089–1098.
34. Bass BL, Weintraub H (1987) A developmentally regulated activity that unwinds RNA duplexes. Cell 48:607–613.
35. Melcher T, et al. (1996) A mammalian RNA editing enzyme. Nature 379:460–464.
36. O’Connell MA, Gerber A, Keegan LP (1998) Purification of native and recombinant double-stranded RNA-specific adenosine deaminases. Methods 15:51–62.
37. Kim U, Wang Y, Sanford T, Zeng Y, Nishikura K (1994) Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci USA 91:11457–11461.
38. Basilio C, Wahba AJ, Lengyel P, Speyer JF, Ochoa S (1962) Synthetic polynucleotides and the amino acid code. V. Proc Natl Acad Sci USA 48:613–616.
39. Bhalla T, Rosenthal JJ, Holmgren M, Reenan R (2004) Control of human potassium channel inactivation by editing of a small mRNA hairpin. Nat Struct Mol Biol 11: 950–956.
40. Sommer B, Köhler M, Sprengel R, Seeburg PH (1991) RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell 67:11–19.
41. Burns CM, et al. (1997) Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 387:303–308.
42. Dawson TR, Sansam CL, Emeson RB (2004) Structure and sequence determinants required for the RNA editing of ADAR2 substrates. J Biol Chem 279:4941–4951.
43. Higuchi M, et al. (1993) RNA editing of AMPA receptor subunit GluR-B: A base-paired intron-exon structure determines position and efficiency. Cell 75:1361–1370.
44. Maas S, et al. (1996) Structural requirements for RNA editing in glutamate receptor pre-mRNAs by recombinant double-stranded RNA adenosine deaminase. J Biol Chem 271:12221–12226.
45. Lomeli H, et al. (1994) Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science 266:1709–1713.
46. Yang JH, Sklar P, Axel R, Maniatis T (1997) Purification and characterization of a human RNA adenosine deaminase for glutamate receptor B pre-mRNA editing. Proc Natl Acad Sci USA 94:4354–4359.
47. Hanswillemenke A, Kuzdere T, Vogel P, Jékely G, Stafforst T (2015) Site-directed RNA editing in vivo can be triggered by the light-driven assembly of an artificial riboprotein. J Am Chem Soc 137:15875–15881.
48. Vogel P, Stafforst T (2014) Site-directed RNA editing with antagomir deaminases–A tool to study protein and RNA function. ChemMedChem 9:2021–2025.
49. Vogel P, Schneider MF, Wettengel J, Stafforst T (2014) Improving site-directed RNA editing in vitro and in cell culture by chemical modification of the guideRNA. Angew Chem Int Ed Engl 53:6267–6271.
50. Schneider MF, Wettengel J, Hoffmann PC, Stafforst T (2014) Optimal guideRNAs for re-directing deaminase activity of hADAR1 and hADAR2 in trans. Nucleic Acids Res 42: e87.
51. Montiel-González MF, Vallecillo-Viejo IC, Rosenthal JJ (2016) An efficient system for selectively altering genetic information within mRNAs. Nucleic Acids Res 44:e157.
52. Montiel-Gonzalez MF, Vallecillo-Viejo I, Yudowski GA, Rosenthal JJ (2013) Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing. Proc Natl Acad Sci USA 110:18285–18290.
53. Austin RJ, Xia T, Ren J, Takahashi TT, Roberts RW (2002) Designed arginine-rich RNA-binding peptides with picomolar affinity. J Am Chem Soc 124:10966–10967.
54. Lyst MJ, et al. (2013) Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat Neurosci 16:898–902.
55. Desterro JM, et al. (2003) Dynamic association of RNA-editing enzymes with the nucleolus. J Cell Sci 116:1805–1818.
56. Wong SK, Sato S, Lazinski DW (2001) Substrate recognition by ADAR1 and ADAR2. RNA 7:846–858.
57. Källman AM, Sahlin M, Ohman M (2003) ADAR2 A–>I editing: Site selectivity and editing efficiency are separate events. Nucleic Acids Res 31:4874–4881.
58. Eggington JM, Greene T, Bass BL (2011) Predicting sites of ADAR editing in double-stranded RNA. Nat Commun 2:319.
59. Lehmann KA, Bass BL (2000) Double-stranded RNA adenosine deaminases ADAR1 and ADAR2 have overlapping specificities. Biochemistry 39:12875–12884.
60. Cuddapah VA, et al. (2014) Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet 51:152–158.
61. Kuttan A, Bass BL (2012) Mechanistic insights into editing-site specificity of ADARs. Proc Natl Acad Sci USA 109:E3295–E3304.
62. Swiech L, et al. (2015) In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 33:102–106.
63. Goffin D, et al. (2011) Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat Neurosci 15:274–283.
64. Brown K, et al. (2016) The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome. Hum Mol Genet 25:558–570.
65. Lagger S, et al. (2017) MeCP2 recognizes cytosine methylated tri-nucleotide and dinucleotide sequences to tune transcription in the mammalian brain. PLoS Genet 13: e1006793.
66. Heckman LD, Chahrour MH, Zoghbi HY (2014) Rett-causing mutations reveal two domains critical for MeCP2 function and for toxicity in MECP2 duplication syndrome mice. eLife 3:e02676.
67. Yang Y, Kucukkal TG, Li J, Alexov E, Cao W (2016) Binding analysis of methyl-CpG binding domain of MeCP2 and Rett syndrome mutations. ACS Chem Biol 11: 2706–2715.
68. Woolf TM, Chase JM, Stinchcomb DT (1995) Toward the therapeutic editing of mutated RNA sequences. Proc Natl Acad Sci USA 92:8298–8302.
69. Nishikura K (2010) Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem 79:321–349.
70. Chen LL, Carmichael GG (2012) Nuclear editing of mRNA 3′-UTRs. Curr Top Microbiol Immunol 353:111–121.
71. Nishikura K (2016) A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol Cell Biol 17:83–96.
72. Matthews MM, et al. (2016) Structures of human ADAR2 bound to dsRNA reveal base-flipping mechanism and basis for site selectivity. Nat Struct Mol Biol 23:426–433.
73. Phelps KJ, et al. (2015) Recognition of duplex RNA by the deaminase domain of the RNA editing enzyme ADAR2. Nucleic Acids Res 43:1123–1132.
74. Wang Y, Beal PA (2016) Probing RNA recognition by human ADAR2 using a high-throughput mutagenesis method. Nucleic Acids Res 44:9872–9880.
75. Matsushita T, et al. (1998) Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 5:938–945.
76. Earley LF, et al. (2017) Adeno-associated virus (AAV) assembly-activating protein is not an essential requirement for capsid assembly of AAV serotypes 4, 5, and 11. J Virol 91:e01980-16.
77. Grimm D, et al. (2003) Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 102:2412–2419.